Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy

Olivier Feron; Chih-Hao Chang; Frédérique Végran

doi:10.3389/fimmu.2023.1171274

Editorial: Targeting glucose metabolism in cancer immunity and immunotherapy

Front Immunol. 2023 Mar 8:14:1171274. doi: 10.3389/fimmu.2023.1171274. eCollection 2023.

Authors

Olivier Feron^{1

2}, Chih-Hao Chang³, Frédérique Végran^{4

5

6

7}

Affiliations

¹ Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.
² WELBIO department, WEL Research Institute, Wavre, Belgium.
³ The Jackson Laboratory, Bar Harbor, ME, United States.
⁴ Université de Bourgogne Franche-Comté, Dijon, France.
⁵ CRI UMR 1231 Lipides, Nutrition and Cancer Team CAdIR, Dijon, France.
⁶ Centre Georges-François Leclerc, UNICANCER, Dijon, France.
⁷ LipSTIC Labex, Dijon, France.

No abstract available

Keywords: GLUT3; fluorodeoxyglucose; gamma-glutamyl hydrolase; glucose transporter; glycolysis; immunometabolism; pancreatic cancer.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Carbohydrate Metabolism
Glucose / metabolism
Humans
Immunotherapy
Neoplasms* / metabolism
Neoplasms* / therapy

Substances

Glucose

Grants and funding

OF is supported by grants from the Fonds de la Recherche Scientifique (F.R.S.-FNRS), the (Belgian) Foundation against cancer, the J. Maisin Foundation and an Action de Recherche Concertée (ARC 19/24-096). OF is a Walloon Excellence in Life Sciences and BIOtechnology (WELBIO) investigator. FV is supported by La Ligue Contre le Cancer.